Evercore ISI analyst Liisa Bayko maintained a Buy rating on Kiniksa Pharmaceuticals (NASDAQ:KNSA) Ltd on Wednesday, setting a price target of $25, which is approximately 66.22% above the present share price of $15.04.
Bayko expects Kiniksa Pharmaceuticals Ltd to post earnings per share (EPS) of -$0.79 for the second quarter of 2021.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in Kiniksa Pharmaceuticals, with an average price target of $31.
The analysts price targets range from a high of $37 to a low of $25.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $0 and a net profit of -$52.9 million. The company's market cap is $1.03 billion.
According to TipRanks.com, Evercore ISI analyst Liisa Bayko is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 13.5% and a 44.88% success rate.
Kiniksa Pharmaceuticals Ltd. is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, KPL-716, KPL-045, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason, and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Hamilton, Bermuda.